Related Experiment Videos
A comparative study of four live measles vaccines in Israel
Abstract:
While an earlier live measles vaccine induced a high degree of immunity it also caused clinical reactions of variable severity in some vaccinated children. A number of attenuated measles vaccine strains have been developed to avoid these problems, and this paper reports the results of small-scale trials with 3 attenuated measles vaccines and a new further-attenuated vaccine on children from 9 months to over 4 years old.All 4 vaccines produced a satisfactory serological response. The new further-attenuated vaccine (Moraten) produced less fever and fewer rashes in the vaccinated children than the other vaccines which had been extensively tested by other workers. The incidence of severe reactions and complications was low with all vaccines.
Insights
New measles vaccines were tested in children. A further-attenuated Moraten vaccine showed fewer side effects like fever and rashes, while maintaining immunity, compared to other tested vaccines.
Area of Science:
- Pediatrics
- Immunology
- Vaccinology
Background:
- Earlier live measles vaccines provided immunity but caused variable clinical reactions.
- Development of attenuated measles vaccine strains aimed to reduce these adverse effects.
Purpose of the Study:
- To evaluate the efficacy and safety of three attenuated measles vaccines and one new further-attenuated vaccine.
- To compare clinical reactions and serological responses in young children.
Main Methods:
- Small-scale clinical trials were conducted on children aged 9 months to over 4 years.
- Four different measles vaccine strains were administered and their effects monitored.
Main Results:
- All four vaccines demonstrated satisfactory serological responses, indicating adequate immunity.
- The new further-attenuated Moraten vaccine resulted in significantly fewer instances of fever and rashes compared to other vaccines.
- Severe reactions and complications were infrequent across all tested vaccine groups.
Conclusions:
- The further-attenuated Moraten measles vaccine offers a favorable safety profile with reduced clinical reactions.
- This new vaccine maintains effective serological responses, making it a promising option for measles prevention in children.